Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

Subcutaneous allergen immunotherapy (SCIT) with aeroallergens is covered for allergic rhinitis/conjunctivitis, allergic asthma, combined rhinitis and asthma, and dust-mite–related atopic dermatitis (after 90 days of failed therapy) when the patient has symptoms on natural exposure and demonstrable specific IgE. SCIT should generally be used after optimized environmental control and pharmacologic therapy (minimum 28 days for medication failure), administered under qualified supervision, and continued for an initial 3–5 year maintenance course with evaluations every 6–12 months; treatment without clinical benefit will not be reimbursed after 2 years.

"SCIT using aeroallergen preparations is reasonable and necessary for allergic rhinitis and/or allergic conjunctivitis (seasonal, perennial, or both)."

Sign up to see full coverage criteria, indications, and limitations.